

Helicobacter Pylori: Foe, Sometimes Friend

by Stephen Olmstead, MD; Kathleen Burns, MSN, RN, NP; Dennis Meiss, PhD; and Janet Ralston, BS

Complete References

1. Dorer MS, Talarico S, Salama NR. Helicobacter pylori's unconventional role in health and disease. PLoS Pathog. 2009;5:e1000544.

2. Bizzozero G. Ueber die schlauchförmigen Drüsen des Magendarmkanals und die Beziehungen ihres Epithels zu dem Oberflächenepithel der Schleimhaut. Dritte mittheilung. Archiv Mikroskopische Anat. 1893;43:82–152.

3. Savage DC. Microbial ecology of the gastrointestinal tract. Annu Rev Microbiol 1977;31:107–133.



4. Adamsson I, Nord CE, Lundquist P, Sjostedt S, Edlund C. Comparative effects of omeprazole, amoxicillin plus metronidazole versus omeprazole, clarithromycin plus metronidazole on the oral, gastric and intestinal microflora in Helicobacter pylori-infected patients. J Antimicrob Chemother. 1999;44:629–460.

5. Warren JR, Marshall BJ. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet. 1983;1:1273–1275.

6. Blaser MJ. Helicobacter pylori and the pathogenesis of gastroduodenal inflammation. J Infect Dis. 1990;161:626–633.

7. Parsonnet J, Friedman GD, Vandersteen DP, et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med. 1991;325:1127–1131.

8. Wotherspoon AC, Ortiz-Hidalgo C, Falzon MR, Isaacson PG. Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma. Lancet. 1991;338:1175–1176.

9. Bik EM, Eckburg PB, Gill SR, et al. Molecular analysis of the bacterial microbiota in the human stomach. J Med Microbiol. 2009;58(Pt 4):509–516.

10. Yamaoka Y. Helicobacter pylori typing as a tool for tracking human migration. Clin Microbiol Infect. 2009;15:829–834.

11. Correa P, Piazuolo MB. Evolutionary history of the *Helicobacter pylori* genome: implications for gastric carcinogenesis. *Gut Liver*. 2012;6:21–28.
12. Kusters JG, van Vliet AH, Kuipers EJ. Pathogenesis of *Helicobacter pylori* infection. *Clin Microbiol Rev J*. 2006;19:449–490.
13. Taniguchi Y, Kimura K, Satoh K, et al. *Helicobacter pylori* detected deep in gastric glands: an ultrastructural quantitative study. *J Clin Gastroenterol*. 1995;21 Suppl 1:S169–S173.
14. Sachs G, Wen Li, Scott DR. Gastric infection by *Helicobacter pylori*. *Curr Gastroenterol Rep*. 2009;11:455–461.
15. Petersen AM, Krogfelt KA. *Helicobacter pylori*: an invading microorganism? A review. *FEMS Immunol Med Microbiol*. 2003;36:117–126.
16. Blaser MJ, Theodore E, Woodward Award: Global warming and the human stomach: microecology follows macroecology. *Trans Am Clin Climatol Assoc*. 2005;116:65–75.
17. Glickman JN, Antonioli DA. Gastritis. *Gastrointest Endosc Clin N Am*. 2001;11:717–740, vii.
18. Corso G, Seruca R, Roviello F. Gastric cancer carcinogenesis and tumor progression. *Ann Ital Chir*. 2012;83:172–176.
19. Ernst PB, Gold BD. The disease spectrum of *Helicobacter pylori*: the immunopathogenesis of gastroduodenal ulcer and gastric cancer. *Annu Rev Microbiol*. 2000;54:615–640.
20. Hunt RH, Sumanac K, Huang JQ. Review article: should we kill or should we save *Helicobacter pylori*? *Aliment Pharmacol Ther*. 2001;15 Suppl 1:51–59.
21. Ahmed N, Tenguria S, Nandanwar N. *Helicobacter pylori* – a seasoned pathogen by any other name. *Gut Pathog*. 2009;1:24.
22. El Serag HB, Sonnenberg A. Opposing time trends of peptic ulcer and reflux disease. *Gut*. 1998;43:327–333.
23. Brown LM, Devesa SS, Chow WH. Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. *J Natl Cancer Inst*. 2008;100:1184–1187.
24. Yamaji Y, Mitsushima T, Ikuma H, et al. Inverse background of *Helicobacter pylori* antibody and pepsinogen in reflux oesophagitis compared with gastric cancer: analysis of 5732 Japanese subjects. *Gut*. 2001;49:335–340.
25. Ye W, Held M, Lagergren J, et al. *Helicobacter pylori* infection and gastric atrophy: risk of

adenocarcinoma and squamous-cell carcinoma of the esophagus and adenocarcinoma of the gastric cardia. J Natl Cancer Inst. 2004;96:388–396.

26. De Martel C, Llosa AE, Farr SM, et al. Helicobacter pylori infection and the risk of development of esophageal adenocarcinoma. J Infect Dis. 2005;191:761–767.

27. Islami F, Kamangar F. Helicobacter pylori and esophageal cancer risk: a meta-analysis. Cancer Prev Res (Phila). 2008;1:329–338.

28. Winberg H, Lindblad M, Lagergren J, Dahlstrand H. Risk factors and chemoprevention in Barrett's esophagus-an update. Scand J Gastroenterol. 2012;47:397–406.

29. Zhou X, Wu J, Zhang G. Association between Helicobacter pylori and asthma: a meta-analysis. Eur J Gastroenterol Hepatol. Epub 2012 Dec 13.

30. Hasni SA. Role of Helicobacter pylori infection in autoimmune diseases. Curr Opin Rheumatol. 2012;24:429–434.

31. Ram M, Barzilai O, Shapira Y, et al. Helicobacter pylori serology in autoimmune diseases – fact or fiction? Clin Chem Lab Med. 2012;0:1–8.

32. Harris PR, Wright SW, Serrano C, et al. Helicobacter pylori gastritis in children is associated with a regulatory T-cell response. Gastroenterology. 2008;134:491–9.

33. Freire de Melo F, Rocha AM, Rocha GA, et al. A regulatory instead of an IL-17 T response predominates in Helicobacter pylori-associated gastritis in children. Microbes Infect. 2012;14:341–347.

34. Boltin D, Niv Y. Ghrelin, Helicobacter pylori and body mass: is there an association? Isr Med Assoc J. 2012;14:130–132.

35. Isomoto H, Nakazato M, Ueno H, et al. Low plasma ghrelin levels in patients with Helicobacter pylori-associated gastritis. Am J Med. 2004;117:429–432.

Invigorate *Your* Mitochondria

ATP 360™ is a complete mitochondrial complex, clinically researched to provide targeted support for...

Mitochondrial Function

- Proprietary phospholipid blend promotes a healthy membrane*
- Antioxidants to support against oxidative stress*
- Healthy membrane is essential for vigorous ATP production*

Krebs Cycle

- Key nutrients to optimize Krebs energy production*

Mitogenesis & Membrane Potential

- Provides nutrients for optimizing the electron transport chain*
- PQQ to promote healthy mitochondrial mass*
- Promote healthy mitochondrial formation*

Visit www.ResearchedNutritionals.com/atp-360 for a full list of ingredients

Researched Nutritionals
Tel: 800.755.3402 • Fax: 805.693.1806 • CustomerService@ResearchedNutritionals.com
www.ResearchedNutritionals.com | Available only through healthcare professionals.

*These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.

36. Nishi Y, Isomoto H, Uotani S, et al. Enhanced production of leptin in gastric fundic mucosa with *Helicobacter pylori* infection. *World J Gastroenterol*. 2005;11:695–699.
37. Ioannou GN, Weiss NS, Kearney DJ. Is *Helicobacter pylori* seropositivity related to body mass index in the United States? *Aliment Pharmacol Ther*. 2005;21:765–772.
38. Redéen S, Petersson F, Törnkrantz E, Levander H, Mårdh E, Borch K. Reliability of diagnostic tests for *Helicobacter pylori* infection. *Gastroenterol Res Pract*. 2011;2011:940650.
39. Kazemi S, Tavakkoli H, Habizadeh MR, Emami MH. Diagnostic values of *Helicobacter pylori* diagnostic tests: stool antigen test, urea breath test, rapid urease test, serology and histology. *J Res Med Sci*. 2011;16:1097–1104.
40. Mishra S, Singh V, Rao GR, et al. Detection of *Helicobacter pylori* in stool specimens: comparative evaluation of nested PCR and antigen detection. *J Infect Dev Ctries*. 2008;2:206–210.
41. Weiss J, Tsang TK, Meng X, et al. Detection of *Helicobacter pylori* gastritis by PCR: correlation with inflammation scores and immunohistochemical and CLOtest findings. *Am J Clin Pathol*. 2008;129:89–96.
42. Malfertheiner P, Megraud F, O'Morain CA, et al. Management of *Helicobacter pylori* infection—the Maastricht IV/ Florence Consensus Report. *Gut*. 2012;61:646–664.
43. Peterson WL, Graham DY, Marshall B, et al. Clarithromycin as monotherapy for eradication of *Helicobacter pylori*: a randomized, double-blind trial. *Am J Gastroenterol*. 1993;88:1860–1864.
44. Malfertheiner P, Mégraud F, O'Morain C, et al. Current European concepts in the management of *Helicobacter pylori* infection—the Maastricht Consensus Report. The European *Helicobacter Pylori* Study Group (EHPHG). *Eur J Gastroenterol Hepatol*. 1997;9:1–2.
45. Donlan RM, Costerton JW. Biofilms: survival mechanisms of clinically relevant microorganisms. *Clin Microbiol Rev*. 2002;15:167–193.
46. Jain A, Gupta Y, Agrawal R, Khare P, Jain SK. Biofilms—a microbial life perspective: a critical review. *Crit Rev Ther Drug Carrier Syst*. 2007;24:393–443.
47. Jefferson KK. What drives bacteria to produce a biofilm? *FEMS Microbiol Lett*. 2004;236:163–173.
48. Stark RM, Gerwig GJ, Pitman RS, et al. Biofilm formation by *Helicobacter pylori*. *Lett Appl Microbiol*. 1999;28:121–126.
49. Coticchia JM, Sugawa C, Tran VR, et al. Presence and density of *Helicobacter pylori* biofilms in human gastric mucosa in patients with peptic ulcer disease. *J Gastrointest Surg*. 2006;10:883–889.
50. Cellini L, Grande R, Di Campli E, et al. Dynamic colonization of *Helicobacter pylori* in human gastric

mucosa. Scand J Gastroenterol. 2008;43:178–185.

51. Chu YT, Wang YH, Wu JJ, Lei HY. Invasion and multiplication of *Helicobacter pylori* in gastric epithelial cells and implications for antibiotic resistance. Infect Immun. 2010;78:4157–4165.

52. Necchi V, Candusso ME, Tava F, et al. Intracellular, intercellular, and stromal invasion of gastric mucosa, preneoplastic lesions, and cancer by *Helicobacter pylori*. Gastroenterology. 2007;132:1009–1023.

53. Malfertheiner P, Selgrad M, Bornschein J. *Helicobacter pylori*: clinical management. Curr Opin Gastroenterol. 2012;28:608–614.

54. Lesbros-Pantoflickova D, Corthésy-Theulaz I, Blum AL. *Helicobacter pylori* and probiotics. J Nutr. 2007;137:812S–818S.

Truly the Best CBD...
Now Validated by a Breakthrough Clinical Study.

TruGen3
TruEase
PHYTOCANNABINOID-RICH HEMP OIL
A DIETARY SUPPLEMENT
30 SOFTGELS

More than 4X the Bioavailability of Ordinary CBD products with MCT.*

TruEase® is truly today's Best-in-Class CBD product, produced under the highest quality and ethical standards, sold only through Health Care Professionals. And now, TruEase® has been validated as the truly superior CBD product in a newly published Clinical Study: "A Novel Self-Emulsifying Drug Delivery System (SEDDS) Based on VESIsorb® Formulation Technology Improving the Oral Bioavailability of Cannabidiol in Healthy Subjects". TruEase® uses patented VESIsorb® technology to provide **over 4X more bioavailability** than ordinary CBD products with MCT.* Order yours today.

TruGen3 Proudly Welcomes Dr. Chris D. Meletis as Chief Clinical CBD Advisor.

- Receive direct access to Dr. Meletis for answers to CBD questions
- VESIsorb® Technology for more than 4X bioavailability*
- Solvent-free Super Critical CO₂ extraction provides undetectable THC levels
- 25mg of CBD & 10mg of beta-caryophyllene

TruGen3
Three Generations of Truth in Nutrition
www.trugen3.com 1-844-387-8436

Call or visit our website today for **FREE SAMPLES** and monthly CBD updates from Dr. Meletis

Scan this QR code to read the complete Clinical Study!
www.trugen3.com/product/truease

55. Gotteland M, Brunser O, Cruchet S. Systematic review: are probiotics useful in controlling gastric colonization by *Helicobacter pylori*? Aliment Pharmacol Ther. 2006;23:1077–86.

56. Felley C, Michetti P. Probiotics and *Helicobacter pylori*. Best Pract Res Clin Gastroenterol. 2003;17:785–791.

57. Vandenplas Y, Brunser O, Szajewska H. *Saccharomyces boulardii* in childhood. Eur J Pediatr. 2009;168:253–265.

58. Lionetti E, Francavilla R, Castellazzi AM, et al. Probiotics and *Helicobacter pylori* infection in children. J Biol Regul Homeost Agents. 2012;26(1 Suppl):S69–S76.

59. McFarland LV. Systematic review and meta-analysis of *Saccharomyces boulardii* in adult patients. World J Gastroenterol. 2010;16:2202–2222.

60. Gotteland M, Poliak L, Cruchet S, Brunser O. Effect of regular ingestion of *Saccharomyces boulardii* plus inulin or *Lactobacillus acidophilus* LB in children colonized by *Helicobacter pylori*. Acta Paediatr. 2005;94:1747–1751.

61. Hurduc V, Plesca D, Dragomir D, Sajin M, Vandenplas Y. A randomized, open trial evaluating the

effect of *Saccharomyces boulardii* on the eradication rate of *Helicobacter pylori* infection in children. *Acta Paediatr.* 2009;98:127–131.

62. Lasa I. Towards the identification of the common features of bacterial biofilm development. *Int Microbiol.* 2006;9:21–28.

63. Olmstead S, Allan N, Omar A, Olson M. Evaluation of nutraceutical enzymes in the treatment of clinically significant gastrointestinal biofilms alone and in combination with relevant antibiotics. Poster presented at the 5th Annual American Society for Microbiology Biofilm Meetings; Nov. 2009.

64. Valenti P, Berlutti F, Conte MP, Longhi C, Seganti L. Lactoferrin functions: current status and perspectives. *J Clin Gastroenterol.* 2004;38(6 Suppl):S127–S129.

65. Singh PK, Parsek MR, Greenberg EP, Welsh MJ. A component of innate immunity prevents bacterial biofilm development. *Nature.* 2002;417:552–555.

66. Di Mario F, Aragona G, Dal Bò N, et al. Use of bovine lactoferrin for *Helicobacter pylori* eradication. *Dig Liver Dis.* 2003;35:706–710.

67. Zou J, Dong J, Yu XF. Meta-analysis: the effect of supplementation with lactoferrin on eradication rates and adverse events during *Helicobacter pylori* eradication therapy. *Helicobacter.* 2009;14:119–127.

68. Cammarota G, Branca G, Ardito F, et al. Biofilm demolition and antibiotic treatment to eradicate resistant *Helicobacter pylori*: a clinical trial. *Clin Gastroenterol Hepatol.* 2010;8:817–820.e3.

69. Boots AW, Haenen GR, Bast A. Health effects of quercetin: from antioxidant to nutraceutical. *Eur J Pharmacol.* 2008;585:325–337.

70. Bischoff SC. Quercetin: potentials in the prevention and therapy of disease. *Curr Opin Clin Nutr Metab Care.* 2008;11:733–740.

71. Brown JC, Jiang X. Activities of muscadine grape skin and polyphenolic constituents against *Helicobacter pylori*. *J Appl Microbiol.* Epub 2013 Jan 7.

72. González-Segovia R, Quintanar JL, Salinas E, Ceballos-Salazar R, Aviles-Jiménez F, Torres-López J. Effect of the flavonoid quercetin on inflammation and lipid peroxidation induced by *Helicobacter pylori* in gastric mucosa of guinea pig. *J Gastroenterol.* 2008;43:441–447.

[**RETURN TO ARTICLE**](#)